Endocannabinoid overactivity and intestinal inflammation

Gut

Volumn 55, Issue 10, 2006, Pages 1373-1376

  Di Marzo, V ^a   Izzo, A A ^b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CAPSAICIN; ENDOCANNABINOID; VANILLOID RECEPTOR 1;

BIOSYNTHESIS; ENTERITIS; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL TRACT; HUMAN; IN VIVO STUDY; INTESTINE MOTILITY; LOWER ESOPHAGUS SPHINCTER; NONHUMAN; PRIORITY JOURNAL; RECEPTOR UPREGULATION; REVIEW; STOMACH ACID SECRETION;

CANNABINOIDS; ENDOCANNABINOIDS; GASTROENTERITIS; GASTROINTESTINAL MOTILITY; HUMANS; RECEPTORS, CANNABINOID;

EID: 33749165439     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.090472     Document Type: Review

References (45)

1. Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Disc 2004;3:771-84.
2. Duncan M, Davison JS, Sharkey Ka. Endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 2005;22:667-83.
3. Coutts AA, Izzo AA. The gastrointestinal pharmacology of cannabinoids. An update. Curr Opin Pharmacol 2004;4:572-9.
4. Hornby PJ, Prouty SM. Involvement of cannabinoid receptors in gut motility and visceral perception. Br J Pharmacol 2004;141:1335-45.
5. Massa F, Storr M, Lutz B. The endocannabinoid system in the physiology and pathophysiology of the gastrointestinal tract. J Mol Mod 2005;83:944-54.
6. Darmani NA. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology 2001;24:198-203.
7. Van Sickle MD, Oland LD, Ho W, et al. Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology 2001;121:767-74.
8. Adami M, Frati P, Bestini S, et al. Gastric antisecretory role and immunohistochemical localization of cannabinoid receptors in the rat stomach. Br J Pharmacol 2002;135:1598-606.
9. Lehmann A, Blackshaw LA, Branden L, et al. Cannabinoid receptor agonism inhibits transient lower esophageal sphincter relaxations and reflux in dogs. Gastroenterology 2002;123:1129-34.
10. Pinto L, Izzo AA, Cascio MG, et al. Endocannabinoids as physiological regulators of colonic propulsion in mice. Gastroenterology 2002;123:227-34.
11. Izzo AA, Capasso F, Costagliola A, et al. An endogenous cannabinoid tone attenuates cholera toxin-induced fluid accumulation in mice. Gastroenterology 2003;125:765-74.
12. Wright K, Rooney N, Feeney M, et al. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology 2005;129:437-53.
13. Mathison R, Ho W, Pittman QJ, et al. Effects of cannabinoid receptor-2 activation on accelerated gastrointestinal transit in lipopolysaccharide-treated rats. Br J Pharmacol 2004;142:1247-54.
14. Van Goal LF, Rissanen AM, Scheen AJ, et al. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
15. Gomez R, Navarro M, Ferrer B, et al. A peripheral mechanism for CB1 cannabinoid receptor-dependent modulation of feeding. J Neurosci 2002;22:9612-17.
16. Mascolo N, Izzo AA, Ligresti A, et al. The endocannabinoid system and the molecular basis of paralytic ileus in mice. FASEB J 2002;16:1973-5.
17. Ligresti A, Bisogno T, Matias I, et al. Possible endocannabinoid control of colorectal cancer growth. Gastroenterology 2003;125:677-87.
18. 2 receptors for endocannabinoids. In: Onaivi ES, Sugiura T, Di Marzo V, eds. Endocannabinoids. The brains's marijuana and beyond. Boca Raton: Taylor & Francis-CRC Press, 2006:151-74.
19. Ward SM, Bayguinov J, Won KJ, et al. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003;465:121-35.
20. McVey DC, Schmid PC, Schmid HH, et al. Endocannabinoids induce ileitis in rats via the capsaicin receptor (VR1). J Pharmacol Exp Ther 2003;304:713-22.
21. 1 cannabinoid receptor. Br J Pharmacol, 2001;134:161-7.
22. Izzo AA, Capasso R, Pinto L, et al. Effect of vanilloid drugs on gastrointestinal transit in mice. Br J Pharmacol 2001;132:1411-16.
23. Moore SA, Nomikos GG, Dickason-Chesterfield AK, et al. Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A 2005;102:17852-7.
24. Katayama K, Ueda N, Kurahashi Y, et al. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochim Biophys Acta 1997;1347:212-18.
25. Capasso R, Matias I, Lutz B, et al. Fatty acid amide hydrolase controls mouse intestinal motility in vivo. Gastroenterology 2005;129:941-51.
26. Di Marzo V, De Petrocellis L. Plant, synthetic, and endogenous cannabinoids in medicine. Annu Rev Med 2006;57:553-74.
27. Izzo AA, Fezza F, Capasso R, et al. Cannabinoid CB1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br J Pharmacol 2001;134:563-70.
28. Cravatt BF, Giang DK, Mayfield SP, et al. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-7.
29. Massa F, Marsicano G, Hermann H, et al. The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 2004;113:1202-9.
30. O'Argenio G, Valenti M, Scaglione G, et al. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation. FASEB J 2006;20:568-70.
31. Klein TW, Lane B, Newton CA, et al. The cannabinoid system and cytokine network. Proc Soc Exp Biol Med 2000;225:1-8.
32. Ihenetu K, Molleman A, Parsons ME, et al. Inhibition of interleukin-8 release in the human colonic epithelial cell line HT-29 by cannabinoids. Eur J Pharmacol 2003;458:207-15.
33. Croci T, Landi M, Galzin AM, et al. Role of cannabinoid CB1 receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 2003;140:115-22.
34. Massa F, Sibaev A, Marsicano G, et al. Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis. J Mol Med 2006;84:142-6.
35. Kihara N, de la Fuente SG, Fujino K, et al. Vanilloid receptor-1 containing primary sensory neurones mediate dextran sulphate sodium induced colitis in rats. Gut 2003;52:713-19.
36. Geppetti P, Trevisani M. Activation and sensitisation of the vanilloid receptor: role in gastrointestinal inflammation and function. Br J Pharmacol 2004;141:1313-20.
37. Fujino K, Takami Y, de la Fuente SG, et al. Inhibition of the vanilloid receptor subtype-1 attenuates TNBS-colitis. J Gastrointest Surg 2004;8:842-7.
38. Goso C, Evangelista S, Tramontana M, et al. Topical capsaicin administration protects against trinitrobenzene sulfonic acid-induced colitis in the rat. Eur J Pharmacol 1993;249:185-90.
39. Guognini F, Valenti M, Mukenge S, et al. Neural contractions in colonic strips from patients with diverticulosis: role of endocannabinoids and substance P. Gut 2006;55:946-53.
40. Facer P, Knowles CH, Tam PK, et al. Novel capsaicin (VR1) and purinergic (P2X3) receptors in Hirschsprung's intestine. J Pediatr Surg 2001;36:1679-84.
41. Press release of the University Hospital of Munich, 3 February 2005 http://idw-online.de/pages/de/news99374 (last accessed 14 July 2006).
42. Smith PF. Cannabinoids as potential anti-epileptic drugs. Curr Clin Investig Drugs 2005;6:680-5.
43. Kimball ES, Schneider CR, Wallace NH, et al. Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 2006;291:G364-71.
44. Darmani NA, Izzo AA, Degenhardt B, et al. Involvement of the cannabimimetic compound, N-palmitoyl-ethanolamine, in inflammatory and neuropathic conditions: Review of the available pre-clinical data, and first human studies. Neuropharmacology 2005;48:1154-63.
45. Capasso R, Izzo AA, Fezza F, et al. Inhibitory effect of palmitoylethanolamide on gastrointestinal motility in mice. Br J Pharmacol 2001;134:945-50.